US EditionPublished • loading... • Updated
Health Check: It’s quarterly report ‘Liberation Day’ for Aroa after a bumper first half result
Summary by Stockhead
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Health Check: It’s quarterly report ‘Liberation Day’ for Aroa after a bumper first half result
With 12 months of consistent positive cash flow, Aroa Biosurgery no longer needs to lodge quarterly reports Monash IVF’s bidder will have to pay more Pacific Edge positions itself for reimbursement resumption Aroa Biosurgery’s (ASX:ARX) star product Myriad continues to deliver the goods and is now the company’s biggest revenue generator. The Kiwi-based soft-tissue-regeneration house today reported product revenue of NZ$44.6 million ($39 milli…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
